Greenwich LifeSciences (GLSI) Expected to Announce Quarterly Earnings on Tuesday

Greenwich LifeSciences (NASDAQ:GLSI) is projected to post its results after the market closes on Tuesday, March 31st. Analysts expect Greenwich LifeSciences to post earnings of ($0.33) per share for the quarter.

Greenwich LifeSciences Price Performance

Shares of NASDAQ GLSI opened at $25.34 on Friday. Greenwich LifeSciences has a 1 year low of $7.78 and a 1 year high of $34.10. The firm has a 50-day moving average of $26.57 and a 200 day moving average of $17.24. The stock has a market cap of $350.96 million, a P/E ratio of -17.36 and a beta of 1.50.

Insider Transactions at Greenwich LifeSciences

In other news, CEO Snehal Patel purchased 4,300 shares of the company’s stock in a transaction that occurred on Wednesday, December 31st. The shares were bought at an average price of $21.36 per share, for a total transaction of $91,848.00. Following the purchase, the chief executive officer directly owned 5,599,402 shares in the company, valued at approximately $119,603,226.72. This trade represents a 0.08% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In the last quarter, insiders have bought 11,900 shares of company stock valued at $288,425. Insiders own 51.47% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in shares of Greenwich LifeSciences by 4.9% in the third quarter. Vanguard Group Inc. now owns 282,181 shares of the company’s stock worth $2,808,000 after buying an additional 13,179 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Greenwich LifeSciences by 6.7% during the fourth quarter. Geode Capital Management LLC now owns 151,684 shares of the company’s stock valued at $3,187,000 after acquiring an additional 9,568 shares in the last quarter. State Street Corp raised its holdings in Greenwich LifeSciences by 19.3% in the 4th quarter. State Street Corp now owns 97,777 shares of the company’s stock worth $2,054,000 after acquiring an additional 15,831 shares during the last quarter. Marshall Wace LLP purchased a new position in Greenwich LifeSciences in the 2nd quarter worth approximately $509,000. Finally, Man Group plc bought a new position in Greenwich LifeSciences in the 4th quarter valued at approximately $590,000. 4.16% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on GLSI shares. HC Wainwright raised their target price on shares of Greenwich LifeSciences from $39.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday, December 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Greenwich LifeSciences in a research report on Monday, December 29th. Finally, Wall Street Zen upgraded Greenwich LifeSciences from a “sell” rating to a “hold” rating in a research note on Saturday, December 27th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Greenwich LifeSciences presently has an average rating of “Hold” and a consensus target price of $47.50.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.